🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

What a milestone for Dr. Nabeel Bardeesy & team to have "Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity" published in Science Magazine! This study was partly funded via C2T2, a CCF Collaboration Award, and 2⃣ Research Fellowships. cholangiocarcinoma.org/6049-2/

Fantastic talk from Dr Vindhya Vijay at the prestigious #cshlcancer24 conference on a currently non-targetable subset of cholangiocarcinoma. Her work, supported by a CCF Research Fellowship, is pushing the field forward! Read her brilliant pre-print: biorxiv.org/content/10.110…

So proud of my talented lab mate and friend for her incredible and impactful work on another rare liver cancer!

7th Asia Pacific 🌍 #Cholangiocarcinoma Conference with KSMO in Seoul 🇰🇷 We are glad to collaborate on this important knowledge sharing platform.

Those in the #Boston, #Houston, #Nashville, and #Seattle areas: Please join others in the #cholangiocarcinoma community for meaningful in-person gatherings in February. Learn more and register: cholangiocarcinoma.org/february-is-cc… #GreenforCCA

💚🌍 Cholangiocarcinoma is on the rise—and awareness is more important than ever. 🌍💚 As the second most common liver cancer, cholangiocarcinoma is frequently misdiagnosed, delaying critical treatment. And with liver and bile duct cancer projected to become the third deadliest

Live from the #AHPBA25 CCA Session! Our team is engaging with leading experts, discussing the latest advancements in cholangiocarcinoma, and strengthening collaborations to support patients. We are grateful for the opportunity to be part of this important conversation.

Honored to present alongside experts, including our incredible MGH team, on multidisciplinary #cholangiocarcinoma management at #AHPBA2025! Cholangiocarcinoma Foundation Flavio G Rocha, MD, FACS, FSSO Kumar Krishnan Motaz Qadan, MD, PhD Shimul A. Shah

And just like that… the 12th Annual Cholangiocarcinoma Foundation Conference comes to a close. 💚 This week was more than a gathering—it was a powerful step forward. Together, patients, caregivers, researchers, and clinicians helped shape the future by identifying the research

63 biliary cancer cell lines!! An unbelievable resource from the Bardeesy Lab Mass General Cancer Center

🚨 New from our lab! Huge congrats to my amazing colleague and friend Vindhya Vijay —so proud of this work! A powerful resource for the cholangio field combining multi-omics and CRISPR screens across 63 biliary tract cancer (BTC) cell lines. Check it out! TargetCancer Fdn Cholangiocarcinoma Foundation

Generation of a biliary tract cancer cell line atlas identifies molecular subtypes and therapeutic targets ⁦Cancer Discovery⁩ ⁦Flavio G Rocha, MD, FACS, FSSO⁩ ⁦Rachna Shroff, MD, MS, FASCO⁩ ⁦Dr. Cathy Eng⁩ aacrjournals.org/cancerdiscover…

Biliary tract cancers are aggressive and understudied. This landmark study,led by my brilliant colleague and friend Vindhya Vijay, profiles 63 BTC cell lines with multi-omics and CRISPR screens, revealing subtypes and vulnerabilities. Honored to contribute! Cholangiocarcinoma Foundation TargetCancer Fdn

New Cancer Discovery: Generation of a BTC Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets - Vindhya Vijay, Negin Karisani, Gad Getz Laboratory, Nabeel Bardeesy, and colleagues doi.org/10.1158/2159-8…… Supported by CCF Research Fellowships and collaboration through C2T2

Thrilled to share our work mapping dependencies in molecularly distinct, lineage-based BTC subtypes. Extremely thankful to TargetCancer Fdn for believing in this work from the very beginning and to Cholangiocarcinoma Foundation for multiple research fellowships that helped make this possible.

massgeneralbrigham.org/en/about/newsr… Mass General Brigham Research Gad Getz Laboratory Francisca Vazquez TargetCancer Fdn Cholangiocarcinoma Foundation

Nabeel Mass General Cancer Center was not ready to accept that “Lack of model systems would prevent the community to study this cancer”. I feel lucky to see it closely and play a small part in the early development. Very inspiring.TargetCancer Fdn

Excited to share our comprehensive cell line atlas for biliary tract cancer (BTC) in collab with Dr. Nabeel Bardeesy Mass General Cancer Center & Francisca Vazquez, and led by Vindhya Vijay & Negin Karisani! doi.org/10.1158/2159-8… The Cancer Dependency Map Cancer Discovery Also see: massgeneralbrigham.org/en/about/newsr…

In a new study, researchers from Mass General Cancer Center and colleagues' 'cell line atlas' provides a crucial resource for developing therapies for biliary tract cancer. The study was published in Cancer Discovery. Read more: massgeneralbrigham.org/en/about/newsr… Gad Getz Laboratory Francisca Vazquez

A new cell line atlas of biliary tract cancers uncovers new subtypes and potential drug targets for better treatment of these deadly diseases. Learn more: broad.io/DepMap-BTCs Mass General Brigham Research TargetCancer Fdn